Insurance clain costs for overactive bladder disorder

Drug Benefit Trends

Volumn 13, Issue 4, 2001, Pages 45-48+53

  Zhou, Z ^a   Jensen, G A ^a  

^a Greenstone Healthcare Solutions   (United States)

Author keywords

Insurance costs; Overactive bladder; Urinary problems

Indexed keywords

CHOLINERGIC RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE;

ARTICLE; BEHAVIOR MODIFICATION; BLADDER DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PREVALENCE; RISK ASSESSMENT; SIDE EFFECT; SOCIAL ASPECT; URINARY DYSFUNCTION; XEROSTOMIA;

EID: 0035037153     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The overactive bladder: An overview for primary care health providers
2. Pharmacologic options for the overactive bladder
3. Epidemiology of overactive bladder
4. Definition of overactive bladder and epidemiology of urinary incontinence
5. Epidemiology of overactive bladder
6. Diagnostic evaluation of urinary incontinence in geriatric patients
7. Toward optimal health: The experts respond to urinary incontinence
8. Informing patients about urinary incontinence
9. International group seeks to dispel incontinence "taboo"
10. Knowledge and beliefs about urinary incontinence in adulthood and old age
11. Midlife women and urinary incontinence: Causes, lifestyles, and treatments
12. Incontinence
13. The impact of urge urinary incontinence on quality of life: Importance of patients' perspective and explanatory style
14. Psychosocial impact of urinary incontinence in women
15. Economic considerations and outcome measurement in urge incontinence
16. The economic impact of urinary incontinence
17. Medically recognized urinary incontinence and risks of hospitalization, nursing home admission and mortality
18. Economic costs of urinary incontinence in 1995
19. Urinary incontinence and depression
20. The influence of urinary incontinence on the quality of life of elderly women
21. Nonsurgical therapies for urinary incontinence
22. Treatment of urinary incontinence among caregiver-dependent adults
23. Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: An education program
24. Behavioral modification for institutionalized individuals with urinary incontinence
25. Behavior therapy for urge incontinence in older women
26. Comparative efficacy of behavioral interventions in the management of female urinary incontinence
27. Home-based management of urinary incontinence: A pilot study with both frail and independent elders
28. Assessment and management of urinary incontinence among homebound older adults: A clinical trial protocol
29. Urinary incontinence: A minor risk factor for hip fractures in elderly women
30. Tolterodine - A new bladder-selective antimuscarinic agent
31. Tolterodine - A new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data
32. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
33. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
34. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
35. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms